The main goal of the Career Development Program is to prepare new investigators for independent careers in lung cancer research. It is expected that Career Development Awardees will spend between two and four years in a productive scientific environment, after which time they will establish independent programs in research related to lung cancer, either at institutions affiliated with the University of Colorado Lung Cancer SPORE or another institution. The Career Development committee annually reviews the progress of each awardee by receiving reports and by discussions with the awardee and the awardee's mentor. The Career Development committee also solicits applications for new awardees. This is done by campus-wide mailings and on some occasions by national letters and journal advertisements. Applicants complete a written application that is reviewed by the committee and the committee also interviews the applicants. The committee makes recommendations to the SPORE Executive Committee which makes final selection and determines the amount of the award in consultation with the applicant and mentor. Institutional funds are used to increase the award amounts above those provided by the grant. For the renewal period we are requesting $50,000 annually. This will be matched with up to $50,000 of institutional funds to provide an average of $50,000 to each of two awardees per year. We believe the program has been successful. Since its inception in 1993, the SPORE has provided support to 20 awardees. Nine of these continue to work on lung cancer. In addition, three other awardees continue scientific investigation in industry and two are academic laboratory investigators. One awardee is in private practice and one retired to care for her family. Three of the awardees are from underrepresented minority groups and 7 are female. No major changes are anticipated in the program with the exception of an increase in the award amounts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058187-18W1
Application #
8719576
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
18
Fiscal Year
2013
Total Cost
$123,330
Indirect Cost
$43,315
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105
DeHart, David N; Lemasters, John J; Maldonado, Eduardo N (2018) Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells. SLAS Discov 23:23-33
Ren, Shengxiang; Zhang, Shucai; Jiang, Tao et al. (2018) Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology 7:e1384108
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543

Showing the most recent 10 out of 435 publications